News

Among Parkinson’s disease (PD) patients who participated in a recent survey, 86% reported experiencing daily “off” episodes — when medication wears off and symptoms return — and 56% don’t think their symptoms can improve beyond their current state. Many patients also were not aware of the availability of adjunctive…

Treatment with cannabidiol (CBD) prevented nerve cell death, extended survival, and reduced toxic protein clumps in nematode worm models of Parkinson’s disease, a new study reports. “These findings supported CBD as an anti-parkinsonian drug,” the researchers wrote, adding that “this CBD neuroprotective action might be due to its antioxidative…

A new analysis using machine-learning and sensor data from the Parkinson’s Progression Markers Initiative (PPMI), a digital health research program sponsored by The Michael J. Fox Foundation for Parkinson’s Research (MJFF), successfully distinguished between people with and without Parkinson’s disease, according to a small study led by…

A new online tool based on artificial intelligence could help reduce possible side effects from anticholinergic medications, a class of therapies often used to control Parkinson’s disease symptoms. “This new tool provides a promising avenue towards a more tailored personalised medicine approach, of ensuring the right person gets a…

IMAC Holdings has completed the dosing of a third and last group of patients who are taking part in a Phase 1 clinical trial that’s testing an investigational stem cell therapy for bradykinesia due to Parkinson’s disease, the company announced. Five patients received a one-time intravenous…

Probiotic supplements were found to ease multiple measures of constipation in people with Parkinson’s disease in a small clinical trial. According to researchers, the use of such supplements also “significantly” improved quality of life for patients with constipation problems. “In this study, multi-strain probiotics were used to treat [Parkinson’s]…

To help expand patient access to treatments and other services, the Parkinson’s Foundation is inviting U.S. medical centers that provide outstanding Parkinson’s disease (PD) clinical care and resources to apply for membership in its Global Care Network. The network comprises Parkinson’s Foundation Centers of Excellence as well as…

Patient dosing has begun in a Phase 2a clinical trial testing oral CST-2032 in combination with CST-107 as a potential way to ease the symptoms of mild cognitive impairment and mild dementia due to Parkinson’s or Alzheimer’s disease, the company developing these therapies, CuraSen Therapeutics, announced. The trial (…

The American Parkinson Disease Association (APDA) will fund a host of Parkinson’s disease research projects for the coming year, including one that will examine the molecular underpinnings of anxiety and another that proposes a treatment for freezing of gait, for a total funding package of $2.35 million, a 25%…

The use of antipsychotic medications is substantially more common among people with Parkinson’s disease than in the general population, according to a new study based on national data in Finland. Results show that the increase in antipsychotic use among Parkinson’s patients is evident several years before the disease is…